Market Overview

UPDATE: Bank of America Raises PT to $70 on Baxter International; Gambro Strategic Fit at Steep Price

Share:
Related BAX
GE And Other Companies In Transition That Insiders Are Buying
Short Interest In Abbott Labs And Baxter International Doubles
Baxter's automated dialysis system approved in Canada (Seeking Alpha)

Bank of America reiterated its Buy rating on Baxter International (NYSE: BAX) and increased its price target from $67 to $70.

Bank of America commented, "On Friday the Wall Street Journal and several other media outlets reported that BAX is in talks to acquire privately held Gambro for $4bn (BAX's market cap is $38bn). Gambro is the #2 share player in the hemodialysis technology market where BAX has little presence, and BAX is #1 in the peritoneal dialysis market where Gambro has no presence. In our view, in the hands of BAX, Gambro would be a much tougher HD competitor and a strong strategic fit, with the potential for significant synergies, but a $4bn price tag creates a very high hurdle for positive returns in our view."

Baxter International closed at $67.18 on Friday.

Latest Ratings for BAX

DateFirmActionFromTo
May 2016Evercore ISI GroupInitiates Coverage onBuy
Apr 2016Credit SuisseMaintainsNeutral
Apr 2016Piper JaffrayUpgradesNeutralOverweight

View More Analyst Ratings for BAX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BAX)

View Comments and Join the Discussion!